Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximabDesmond Curran, Jordi Giralt, Paul M Harari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignanciesMonica Mita, Kevin R Kelly, Alain Mita, et al.
Investigational New Drugs|September 15, 2010
Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignanciesLisa A Hammond-Thelin, Melanie B Thomas, Michiko Iwasaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancerQuincy S C Chu, Mary E Cianfrocca, Lori J Goldstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumorsAmita Patnaik, Debra Wood, Anthony W Tolcher, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2011
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancerHeather A Wakelee, Chris H Takimoto, Arturo Lopez-Anaya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignanciesQuincy Siu-Chung Chu, Lisa A Hammond, Garry Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2004
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasmsLisa A Hammond, John R Eckardt, John G Kuhn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumorsAlain C Mita, Lisa A Hammond, Peter L Bonate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumorsAlejandro D Ricart, Jordan D Berlin, Kyriakos P Papadopoulos, et al.
Pageof 12